골다공증의 치료

참고문헌 (136)

1. "Physician's guide to prevention and treatment of osteoporosis. www.nof.org" (2002)
2. "The world wide problem of osteoporosis insights afforded by epidemiology.", 17, pp.5055~5155 (1995)
3. "Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy.", 285, pp.785~795 (2001)
4. "Epidemiology and outcomes of osteoporotic fractures.", 359, pp.1761~1767 (2002)
5. "Risk of mortality following clinical fractures.", 11, pp.556~561 (2000)
6. "Hip fracture", 334, pp.1519~1525 (1996)
7. "Mortality after all major types of osteoporotic fracture in men and women: an observational study.", 353, pp.878~882 (1999)
8. "Vertebral fractures and mortality in older women.", 159, pp.1215~1220 (1999)
9. "et al. Incidence of clinically diagnosed vertebral fractures a population based study in Rochester", pp.221~7
10. "Osteoporosis: a clinical guide." (1998), Livery HouseLivery House
11. "Impact of hip and vertebral fractures on quality-adjusted life years.", pp.1042~1049 (2001)
12. "The bone organ system. In:", pp.3~19 (2001), Academic Press
13. "Bone densitometry:the best way to detect osteoporosis and to monitor therapy.", 84, pp.1867~1871 (1999)
14. "The biomechanical basis of vertebral body fragility in men and women.", 16, pp.2276~2283 (2001)
15. "Genetic control of susceptibility to osteoporosis.", 87, pp.2460~2466 (2002)
16. "Sex steroids and bone", 81, pp.419~447 (2001)
17. "The use of biochemical markers of bone turnover in osteoporosis.", 11, pp.2~17 (2000)
18. "Pathophysiology of osteoporosis.", 27, pp.255~265 (1998)
19. "Risk factors for osteoporotic fracture.", 27, pp.289~295 (1998)
20. "Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988", pp.1701~7
21. "et al. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA 1994", pp.128~33
22. "Secondary causes of osteoporosis.", 77, pp.53~68 (2002)
23. "Drug-induced bone loss.", 11, pp.637~659 (2000)
24. "Risk factors for hip fracture in white women.", 332, pp.767~773 (1995)
25. "Meta-analysis of how well measures of bone mineral density predict occurrences of osteoporotic fractures.", 312, pp.254~259 (1996)
26. "The challenges of peripheral bone density testing: which patients need additional central density skeletal measurements?", 1, pp.211~217 (1998)
27. "et al. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993", pp.1227~33
28. "Management of postmenopausal osteoporosis position statement of the North American Menopause Society.", 9, pp.84~101 (2002), North American Menopause Society.
29. "NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Treatment. Osteoporosis, prevention and treatment.", 285, pp.785~795 (2001)
30. "Management of osteoporosis.", 44, pp.175~207 (1999)
31. "Diagnosis of osteoporosis and assessment of fracture.", 359, pp.1929~1936 (2002)
32. "Biochemical markers of bone turnover and prediction of hip bone loss in older women the study of osteoporotic fractures.", 14, pp.1404~1410 (1999)
33. "Physical activity, falls and fractures among older adults: a review of the epidemiologic evidence.", 48, pp.883~893 (2000)
34. "Is there a role for exercise in the prevention of osteoporotic fractures", 33, pp.378~386 (1999)
35. "et al. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. JAMA 1994" (1909), Fiatarone MA
36. "Role of exercise in preventing and treating osteoporosis.", 27, pp.131~141 (2001)
37. "Working with patients to prevent a curriculum guide for the health professions." (2001), Duke University
38. "Smoking and bone metabolism in elderly women.", 27, pp.429~436 (2000)
39. "Risk factors for perimenopausal fractures: a prospective study.", 11, pp.219~227 (2000)
40. "Association of fractures with caffeine and alcohol in postmenopausal women: the Iowa Women's Health Study", 3, pp.253~261 (2000)
41. "Epidemiology of medication-related falls and fractures in the elderly.", 12, pp.43~53 (1998)
42. "The use of calcium in the management of osteoporosis.", 24, pp.279~290 (1999)
43. "et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. N Engl J Med 1990", pp.878~83
44. "The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women.", 130, pp.897~904 (1999)
45. "et al. Calcium supplementation with and without hormone replacement therapy to prevent postmenopausal bone loss. Ann Intern Med 1994", pp.97~103
46. "Rationale for active vitamin D analog therapy in senile osteoporosis.", 60, pp.100~105 (1997)
47. "Vitamin D supplementation and fracture incidence in elderly persons.", 124, pp.400~406 (1996)
48. "Calcium for prevention of osteoporotic fractures in postmenopausal women.", 12, pp.1321~1329 (1997)
49. "Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older.", 337, pp.670~676 (1997)
50. "The role of calcium and vitamin D in the prevention of osteoporosis.", 27, pp.389~398 (1998)
51. "NIH Consensus Development Panel on Optimal Calcium Intake. Optimal calcium intake. JAMA 1994" (1942)
52. "Standing Committee on the Scientific Evaluation of Dietary Reference Intake, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride." (1997), National Academy Press
53. "Vitamin K intake and hip fractures in women: a prospective study.", 69, pp.74~79 (1999)
54. "Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease", 61, pp.605~712 (2001)
55. "Alendronate: an update of its use in osteoporosis.", 61, pp.999~1039 (2001)
56. "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.", 282, pp.1344~1352 (1999)
57. "Esophagitis associated with the use of alendronate.", 335, pp.1016~1021 (1996)
58. "Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.", 338, pp.485~492 (1998)
59. "Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial.", 128, pp.253~261 (1998)
60. "Effect of alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis.", 333, pp.1437~1443 (1995)
61. "Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures.", 280, pp.2077~2082 (1998)
62. "Skeletal benefits of alendronate 7-year treatment of postmenopausal osteoporotic women.", 85, pp.3109~3115 (2000)
63. "Risedronate increases bone mass in an early postmenopausal population two years of treatment plus one year of follow-up.", 83, pp.396~402 (1998)
64. "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.", 11, pp.83~91 (2000)
65. "Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures.", 280, pp.2077~2082 (1998)
66. "Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures.", 348, pp.1535~1541 (1996)
67. "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis.", 282, pp.1344~1352 (1999)
68. "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis.", 11, pp.83~91 (2000)
69. "Sustained fracture risk reduction over 5 years with risedronate therapy. Paper presented at American Society of Bone and Mineral Research 23rd Annual Meeting. Phoenix" (2001)
70. "Effect of risedronate on the risk of hip fracture in elderly women.", 344, pp.333~340 (2001)
71. "Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis.", 12, pp.1~12 (2000)
72. "Once-a-week (35 mg) risedronate is as effective as daily (5 mg).", 13, pp.16~ (2002)
73. "Efficacy of once-a-week risedronate in reducing vertebral fracture risk.", 13, pp.17~18 (2002)
74. "Long-term effects of raloxifene on bone mineral density and serum lipid levels in early post-menopausal women.", 160, pp.3044~3050 (2000)
75. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial.", 282, pp.637~645 (1999)
76. "Long-term effects of raloxifene on bone mineral density and serum lipid levels in early post-menopausal women.", 160, pp.3044~3050 (2000)
77. "Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women.", 279, pp.1445~1451 (1998)
78. "Effects of raloxifene on bone mineral density and uterine endometrium in postmenopausal women.", 337, pp.1641~1647 (1997)
79. "Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial", 287, pp.847~257 (2002)
80. "Cognitive function in postmenopausal women treated with raloxifene.", 344, pp.1207~1213 (2001)
81. "Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial.", 949, pp.181~185 (2000)
82. "The effect of raloxifene on risk of breast cancer in postmenopausal women.", 281, pp.2189~2197 (1999)
83. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene results from a 3-year randomized clinical trial.", 282, pp.637~645 (1999)
84. "Bazedoxifene+ conjugated estrogens: a balanced combination to provide optimal “estrogenic” safety and efficacy.", 18, pp.272~ (2002)
85. "et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis", pp.556~61, Overgaard K
86. "Effect of nasal salmon calcitonin on bone remodeling and bone mass in post-menopausal osteoporosis.", 18, pp.207~212 (1996)
87. "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the Prevent Recurrence of Osteoporotic Fractures Study.", 109, pp.267~276 (2000)
88. "et al. Analgesic effect of salmon-calcitonin in osteoporotic vertebral fractures", pp.369~72
89. "Peggs JF. Calcitonin in the treatment of osteoporotic bone pain. J Fam Pract 1992", pp.93~6
90. "Effects of hormone therapy on bone mineral density.", 276, pp.1389~1396 (1996)
91. "Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial.", 286, pp.815~820 (2001)
92. "Timing of postmenopausal estrogen for optimal bone mineral density.", 277, pp.543~547 (1997)
93. "et al. The effects of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993", pp.1141~6
94. "The effect of low dose micronized 17ss-estradiol on bone turnover and side effects in older women: a randomized, double blind, placebo-controlled study.", 85, pp.4462~4469 (2000)
95. "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.", 287, pp.2668~2276 (2002)
96. "et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992", pp.1~9
97. "Estrogen replacement therapy and fractures in older women.", 122, pp.9~16 (1995)
98. "et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992", pp.1016~37
99. "Do estrogens effectively prevent osteoporosis-related fractures?", 67, pp.191~194 (2000)
100. "Hormone replacement therapy and prevention of nonvertebral fractures a meta-analysis of randomized trials.", 285, pp.2891~2897 (2001)
101. "Postmenopausal hormone replacement therapy.", 288, pp.872~881 (2002)
102. "Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial.", 288, pp.321~333 (2002)
103. "Prescribing hormone replacement therapy for menopausal symptoms.", 131, pp.605~616 (1999)
104. "Oral oestrogen replacement therapy versus placebo for hot flushes.", 4, pp.58~74 (2001)
105. "Effects of raloxifene and alendronate on mineral density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.", 87, pp.985~992 (2002)
106. "Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.", 84, pp.3076~3081 (1999)
107. "Alendronate and estrogen effects in postmenopausal women with low bone mineral density.", 85, pp.720~726 (2000)
108. "Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.", 86, pp.1890~1897 (2001)
109. "The anabolic effects of parathyroid hormone.", 13, pp.267~277 (2002)
110. "Reconstructing the skeleton with intermittent parathyroid hormone.", 12, pp.281~283 (2001)
111. "Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.", 16, pp.1846~1853 (2001)
112. "Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis.", 344, pp.1434~1441 (2001)
113. "et al. Intermittant cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990", pp.73~9
114. "Cyclic etidronate in the treatment of postmenopausal osteoporosis efficacy and safety after seven years of treatment.", 103, pp.468~476 (1997)
115. "et al. Two years' effectiveness of intravenous pamidronate versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporos Int 1994", pp.76~83
116. "Cyclic pamidronate infusions in postmenopausal osteoporosis.", 25, pp.69~75 (1996)
117. "Intravenous zolendronic acid in post-menopausal women with low bone mineral density.", 346, pp.653~661 (2002)
118. "et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990", pp.286~90
119. "et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991", pp.370~3
120. "et al. Effects of thiazide diuretic therapy on bone mass", pp.666~73
121. "Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults: a randomized, double-blinded, placebo-controlled trial.", 133, pp.516~526 (2000)
122. "Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial.", 109, pp.362~370 (2000)
123. "Stimulation of bone formation in vitro and in rodents by statins.", 286, pp.1946~1949 (1999)
124. "Statin use, bone mineral density, and fracture risk. Geelong Osteoporosis Study", 162, pp.537~540 (2002)
125. "HMG-CoA reductase inhibitors and the risk of fractures.", 283, pp.3205~3210 (2000)
126. "HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients.", 283, pp.3211~3216 (2000)
127. "Effect of pravastatin on frequency of fracture in the LIPID study secondary analysis of a randomised controlled trial.", 357, pp.509~512 (2001)
128. "Does statin use reduce risk of fracture in postmenopausal women Results from the Women's Health Initiative Observational Study(WHI-OS).", 15, pp.1155~ (2000)
129. "The phytoestrogen genistein reduced bone loss in short-term ovariectomized rats.", 8, pp.274~281 (1998)
130. "Soy protein and isoflavones: their effects on blood lipids and bone density in post-menopausal women.", 68, pp.1375~1379 (1998)
131. "Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women.", 72, pp.844~852 (2000)
132. "Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years.", 7, pp.119~125 (1997)
133. "A double blind placebo- controlled trial of ipriflavone for prevention of postmenopausal spinal bone loss.", 61, pp.142~147 (1997)
134. "Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass.", 61, pp.19~22 (1997)
135. "Bone densitometry: choosing the right skeletal site to measure.", 1, pp.279~285 (1998)
136. "Management of osteoporosis.", 44, pp.175~207 (1999)

관련 논문AI추천